Thrombin Generation is Associated With CA 19-9 In Vitro and in Pancreatic Ductal Adenocarcinoma

被引：0
|
作者：
Mattila, N. [1 ,2 ,3 ]
Przybyla, B. [2 ,3 ]
Seppanen, H. [1 ,2 ]
Haglund, C. [1 ,2 ,4 ]
Lassila, R. [2 ,3 ,5 ]
机构：
[1] Univ Helsinki, Dept Surg, Helsinki, Finland
[2] Helsinki Univ Hosp, Helsinki, Finland
[3] Univ Helsinki, Dept Hematol, Coagulat Disorders Unit, Ctr Comprehens Canc, Helsinki, Finland
[4] Univ Helsinki, Res Programs Unit, Translat Canc Biol, Helsinki, Finland
[5] HUSLAB Lab Serv, Clin Chem, Helsinki, Finland
来源：
PANCREAS | 2018年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1409 / 1409
页数：1
相关论文
共 50 条
  • [41] Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
    Maithel, Shishir K.
    Maloney, Stephen
    Winston, Corrine
    Goenen, Mithat
    D'Angelica, Michael I.
    DeMatteo, Ronald P.
    Jarnagin, William R.
    Brennan, Murray F.
    Allen, Peter J.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) : 3512 - 3520
  • [42] Exploring the role of CA 19-9 level as a predictor of survival in patients with advanced pancreatic adenocarcinoma
    Bekaii-Saab, T.
    Majumber, A.
    Trolli, E.
    Thomas, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 391 - 391
  • [43] Extraordinarily high serum CA 19-9 in setting of pancreatic necrosis and underlying pancreatic adenocarcinoma: a case report
    McConnell, Ashlyn
    Stoneman, Tyler
    Hewlett, Stanley
    JOURNAL OF SURGICAL CASE REPORTS, 2023, 2023 (10):
  • [44] Hs-CRP, Albumin, and CA 19-9 After Neoadjuvant Therapy Predict Postoperative Survival in Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Nurmi, A.
    Mustonen, H.
    Stenman, U. H.
    Haglund, C.
    Seppanen, H.
    PANCREAS, 2018, 47 (10) : 1414 - 1414
  • [45] Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma
    Boyev, Artem
    Prakash, Laura R.
    Chiang, Yi-Ju
    Newhook, Timothy E.
    Bruno, Morgan L.
    Arvide, Elsa M.
    Dewhurst, Whitney L.
    Kim, Michael P.
    Ikoma, Naruhiko
    Lee, Jeffrey E.
    Snyder, Rebecca A.
    Tzeng, Ching-Wei D.
    Katz, Matthew H. G.
    Maxwell, Jessica E.
    SURGICAL ONCOLOGY-OXFORD, 2023, 51
  • [46] The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
    George, Ben
    Kent, Matthew
    Surinach, Andy
    Lamarre, Neil
    Cockrum, Paul
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma
    Nagao, Mina
    Oshima, Minoru
    Suto, Hironobu
    Sugimoto, Masahiro
    Enomoto, Ayame
    Murakami, Tomomasa
    Shimomura, Ayaka
    Wada, Yukiko
    Matsukawa, Hiroyuki
    Ando, Yasuhisa
    Kishino, Takayoshi
    Kumamoto, Kensuke
    Kobara, Hideki
    Kamada, Hideki
    Masaki, Tsutomu
    Soga, Tomoyoshi
    Okano, Keiichi
    PANCREAS, 2024, 53 (04) : e301 - e309
  • [48] Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes
    Guo, Qingqu
    Kang, Muxing
    Zhang, Bo
    Chen, Ying
    Dong, Xin
    Wu, Yulian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (11) : 1627 - 1631
  • [49] IMMUNOHISTOCHEMICAL LOCALIZATION OF CA 19-9 AND CEA IN PANCREATIC-CARCINOMA AND ASSOCIATED DISEASES
    ICHIHARA, T
    NAGURA, H
    NAKAO, A
    SAKAMOTO, J
    WATANABE, T
    TAKAGI, H
    CANCER, 1988, 61 (02) : 324 - 333
  • [50] CA-19-9 AND PANCREATIC ADENOCARCINOMA
    SAFI, F
    BEGER, HG
    BITTNER, R
    BUCHLER, M
    KRAUTZBERGER, W
    CANCER, 1986, 57 (04) : 779 - 783
12345